Microvascular Complications of Diabetes 2

Categories: Genetic diseases, Nephrological diseases, Cardiovascular diseases, Eye diseases, Neuronal diseases

Aliases & Classifications for Microvascular Complications of Diabetes 2

MalaCards integrated aliases for Microvascular Complications of Diabetes 2:

Name: Microvascular Complications of Diabetes 2 54 71 29 13
Proliferative Diabetic Retinopathy 71 69
Diabetic Nephropathy 71 69
Diabetic End-Stage Renal Disease 71
Mvcd2 71


External Ids:

OMIM 54 612623
MeSH 42 D048909

Summaries for Microvascular Complications of Diabetes 2

UniProtKB/Swiss-Prot : 71 Microvascular complications of diabetes 2: Pathological conditions that develop in numerous tissues and organs as a consequence of diabetes mellitus. They include diabetic retinopathy, diabetic nephropathy leading to end-stage renal disease, and diabetic neuropathy. Diabetic retinopathy remains the major cause of new-onset blindness among diabetic adults. It is characterized by vascular permeability and increased tissue ischemia and angiogenesis.

MalaCards based summary : Microvascular Complications of Diabetes 2, also known as proliferative diabetic retinopathy, is related to microvascular complications of diabetes 1 and microvascular complications of diabetes 3. An important gene associated with Microvascular Complications of Diabetes 2 is EPO (Erythropoietin). The drugs Insulin Glargine and Insulin Lispro have been mentioned in the context of this disorder. Affiliated tissues include kidney, testes and bone.

Description from OMIM: 612623

Related Diseases for Microvascular Complications of Diabetes 2

Diseases in the Microvascular Complications of Diabetes 1 family:

Microvascular Complications of Diabetes 4 Microvascular Complications of Diabetes 7
Microvascular Complications of Diabetes 6 Microvascular Complications of Diabetes 2
Microvascular Complications of Diabetes 5 Microvascular Complications of Diabetes 3

Diseases related to Microvascular Complications of Diabetes 2 via text searches within MalaCards or GeneCards Suite gene sharing:

id Related Disease Score Top Affiliating Genes
1 microvascular complications of diabetes 1 11.3
2 microvascular complications of diabetes 3 11.3
3 epidural abscess 9.8
4 kidney disease 9.8
5 peritonitis 9.8

Graphical network of the top 20 diseases related to Microvascular Complications of Diabetes 2:

Diseases related to Microvascular Complications of Diabetes 2

Symptoms & Phenotypes for Microvascular Complications of Diabetes 2

Clinical features from OMIM:


Drugs & Therapeutics for Microvascular Complications of Diabetes 2

Drugs for Microvascular Complications of Diabetes 2 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 103)
id Name Status Phase Clinical Trials Cas Number PubChem Id
Insulin Glargine Approved Phase 4 160337-95-1
Insulin Lispro Approved Phase 4 133107-64-9
Zinc Approved Phase 4,Phase 3,Phase 1 7440-66-6 32051 23994
Metformin Approved Phase 4,Phase 3 657-24-9 14219 4091
Aspirin Approved, Vet_approved Phase 4,Phase 3 50-78-2 2244
Glimepiride Approved Phase 4,Phase 3 93479-97-1 3476
Allopurinol Approved Phase 4 315-30-0 2094
8 Hypoglycemic Agents Phase 4,Phase 3,Phase 1
9 insulin Phase 4,Phase 3,Phase 2
10 Insulin, Globin Zinc Phase 4,Phase 3,Phase 2
11 Antioxidants Phase 4,Phase 1
12 Atorvastatin Calcium Phase 4 134523-03-8
13 Calcium, Dietary Phase 4
14 Hydroxymethylglutaryl-CoA Reductase Inhibitors Phase 4
15 Protective Agents Phase 4,Phase 1
16 Insulin, Isophane Phase 4
17 Isophane insulin, beef Phase 4
18 Isophane Insulin, Human Phase 4
19 Anti-Arrhythmia Agents Phase 4,Phase 3
20 Immunosuppressive Agents Phase 4,Phase 3
21 Analgesics Phase 4,Phase 3
22 Analgesics, Non-Narcotic Phase 4,Phase 3
23 Anticholesteremic Agents Phase 4
24 Anti-Inflammatory Agents Phase 4,Phase 3
25 Anti-Inflammatory Agents, Non-Steroidal Phase 4,Phase 3
26 Antimetabolites Phase 4
27 Antipyretics Phase 4,Phase 3
28 Antirheumatic Agents Phase 4,Phase 3
29 Cyclooxygenase Inhibitors Phase 4,Phase 3
30 Fibrinolytic Agents Phase 4,Phase 3
31 Hypolipidemic Agents Phase 4
32 Lipid Regulating Agents Phase 4
33 Peripheral Nervous System Agents Phase 4,Phase 3
34 Platelet Aggregation Inhibitors Phase 4,Phase 3
35 Cholestyramine Resin Phase 4
Benzocaine Approved Phase 3 1994-09-7, 94-09-7 2337
Rosiglitazone Approved, Investigational Phase 3 122320-73-4 77999
38 tannic acid Approved, Nutraceutical Phase 3
Ruboxistaurin Investigational Phase 3 202260-21-7, 169939-94-0 153999
40 Incretins Phase 2, Phase 3
Folic Acid Approved, Nutraceutical, Vet_approved Phase 1, Phase 2 59-30-3 6037
Thiamine Approved, Nutraceutical, Vet_approved Phase 1, Phase 2 59-43-8 1130
43 Micronutrients Phase 1, Phase 2
44 Trace Elements Phase 1, Phase 2
45 Vitamins Phase 1, Phase 2
46 Adjuvants, Immunologic Phase 1, Phase 2
47 Benphothiamine Phase 1, Phase 2
48 Chelating Agents Phase 1, Phase 2
49 Vitamin B Complex Phase 1, Phase 2
50 arginine Nutraceutical Phase 1, Phase 2

Interventional clinical trials:

(show top 50) (show all 55)

id Name Status NCT ID Phase Drugs
1 Glargine Versus NPH in Patients With Chronic Kidney Disease Completed NCT02451917 Phase 4 Glargine;NPH insulin
2 Insulin Glargine (Lantus) vs Sulfonylurea (SU) for BETA Cell Function (BETA Study) Completed NCT00562172 Phase 4 Insulin glargine;Glimepiride;Metformin
3 Long-Term Effects of Insulin Plus Metformin Regimens on the Overall and Postprandial Glycemic Control of Patients With Type 2 Diabetes Completed NCT00191464 Phase 4 premeal insulin lispro mixtures;insulin glargine;metformin
4 Making Ramadhan Fasting a Safer Experience With Technology Study Completed NCT02189135 Phase 4
5 Effect of Allopurinol on Mono and Co-administration With Statins on Platelets Reactivity on Diabetic Patiets Treated With Aspirin and Insulin Recruiting NCT03195153 Phase 4 Atorvastatin 80mg;ALLOPURINOL 300 MG;Atorvastatin 80mg AND allopurinol 300 mg
7 Diabetes Prevention Program Outcomes Study Unknown status NCT00038727 Phase 3 Metformin
8 Glycemic Control and Complications in Diabetes Mellitus Type 2 (VADT) Completed NCT00032487 Phase 3 Insulin;Glimepiride;Rosiglitazone;Metformin
9 The HOME Trial: Hyperinsulinaemia: the Outcome of Its Metabolic Effects, a Randomized Controlled Trial Completed NCT00375388 Phase 3 Metformin on top of intensive insulin therapy
10 Treatment Options for Type 2 Diabetes in Adolescents and Youth (TODAY) Completed NCT00081328 Phase 3 Metformin;Rosiglitazone
11 OatMeal and Insulin Resistance: OMA-IR Completed NCT00401453 Phase 3
12 Renal and Peripheral Hemodynamic Function in Patients With Type 1 Diabetes Mellitus Completed NCT00297401 Phase 3 ruboxistaurin;placebo
13 The Efficacy of Bariatric Surgery Compared to Medical Therapy in Controlling Type2 Diabetes Mellitus in Patients With Non Morbid Obesity. Recruiting NCT02036138 Phase 2, Phase 3 Advanced Medical Therapy
14 Aspirin and Renal Disease Progression in Patients With Type 2 Diabetes Not yet recruiting NCT02895113 Phase 3 Aspirin
15 Arginase Inhibition and Microvascular Endothelial Function in Type 2 Diabetes Completed NCT02687152 Phase 1, Phase 2
16 Effects of Vitamin B1 in Type 1 Diabetic Patients Completed NCT00117026 Phase 1, Phase 2 Placebo;Benfotiamine
17 Islet Cell Transplantation Alone in Patients With Type 1 Diabetes Mellitus: Steroid-Free Immunosuppression Active, not recruiting NCT00306098 Phase 2 islets
18 Vitamin C Supplementation Plus Hypoglycemic Agents Versus Hypoglycemic Agents Alone in Type 2 Diabetes Mellitus Unknown status NCT01319734 Phase 1 glyburide
19 Prevention and Treatment Of Diabetes Complications With Gastric Surgery or Intensive Medicines Unknown status NCT01974544 Best medical treatment;General interventions for all groups: blood presure;General interventions for all groups: dysilipidemia
20 A Comprehensive Longitudinal Cohort Study in Type 2 Diabetes With High Risk of Cardiovascular Diseases in China Unknown status NCT01307410
21 Correlation Between Vitamin D Levels to ADAMTS13 , VWF and Micro RNA Expression in Diabetic Hemodialysis Patients Unknown status NCT02245633
22 Long-term of 10 Years Results of a Prospective Longitudinal Study Unknown status NCT01557972
23 MoCa Test for the Early Detection of Mild Cognitive Impairment During Annual Assessment of Young Adults With Diabetes and in a Control Group Without Diabetes Unknown status NCT02545062
24 Study TO Prevent Diabetes With Short-term Insulin Glargine Only Unknown status NCT01276912 Insulin glargine
25 The Effects of Glycemic Optimization Before Gastric Bypass Surgery Completed NCT01353118
26 Serum 1,25-dihydroxyvitamin D Levels in Type 2 Diabetes Mellitus Patients With Different Levels of Albuminuria Completed NCT01845870
27 Effect of Gastric Bypass Surgery on Diabetes Status and Microvascular Complications in Obese Type 2 Diabetic Patients Completed NCT02625649
28 PRF Growth Factors Levels in Diabetic Patients With Chronic Periodontitis Completed NCT02304497
29 Quality of Life and Treatment Satisfaction of People With Type 2 Diabetes: A European Survey Completed NCT00916513
30 Resolution of Type 2 Diabetes Mellitus: Intensive vs. Conventional Glycaemic Control After Obesity Surgery Completed NCT01257087 Insulin
31 A Cohort Study of Morning Home Blood Pressure Measurement in Type 2 Diabetic Patients Completed NCT00760110
32 Evolution of Effectiveness of Diabetes Medical Care in Russia Completed NCT02574195
33 TODAY2 Phase 1 Immediate Post-Intervention Observational Follow-up Study Completed NCT01364350
34 Complications in Central American Diabetic Patients: Historic Cohort Completed NCT02486237
35 The ADDITION Study. Intensive Treatment in People With Screen Detected Diabetes in Primary Care. Completed NCT00237549
36 Prospective Study of Diabetes-related Vascular Disease in Oklahoma Indians Completed NCT00005193
37 Angiotensin II Antagonism of TGF-Beta 1 Completed NCT00320970 Candesartan
38 Impact on Birth Weight of Two Therapeutic Strategies (Insulin Therapy From the Beginning of Pregnancy vs. Insulin Therapy Initiated According to Fetal Growth Evaluated by Ultrasonography Measurements) in Pregnant Women With Monogenic Diabetes Recruiting NCT02556840
39 HbA1c Variability in Type II Diabetes Recruiting NCT02879409 Metformin;Gliclazide;Sitagliptin;Liraglutide;Pioglitazone;Dapagliflozin;human insulin
40 Nephrologic Prognosis 10 Years After Diabetes Cell Therapy Recruiting NCT02627690
41 Prevention of Microvascular Complications in Prediabetes e-PREDICE Study Recruiting NCT03222765 Placebo, metformin, linagliptin, linagliptin + metformin
42 A Combined Biofeedback-virtual Reality System for Reduction of Fear of Hypoglycemia Recruiting NCT02380339
43 Prevalence and Incidence of Complications of Type One Diabetes in pUne at a Tertiary Care centRE Recruiting NCT03069196
44 Swiss Diabetes Registry - SwissDiab Study Recruiting NCT01179815
45 Coronary Artery Plaque Burden and Morphology in Type 2 Diabetes Mellitus. Recruiting NCT03016910
46 Clinical Study on Metabolic Surgery Compared to the Best Clinical Treatment in Patients With Type 2 Diabetes Mellitus Active, not recruiting NCT01821508
47 Low-dose Colchicine in Patients With Type 2 Diabetes Mellitus and Microalbuminuria Active, not recruiting NCT02035891 colchicine 0.5mg/d;placebo 0.5mg/d
48 DISCOVERing Treatment Reality of Type 2 Diabetes in Real World Setting in Japan Active, not recruiting NCT02226822
49 Look AHEAD: Action for Health in Diabetes Active, not recruiting NCT00017953
50 Disease Prevention in Clinical Practice Base on Patient Specific Physiology Enrolling by invitation NCT03308773

Search NIH Clinical Center for Microvascular Complications of Diabetes 2

Inferred drug relations via UMLS 69 / NDF-RT 48 :

Genetic Tests for Microvascular Complications of Diabetes 2

Genetic tests related to Microvascular Complications of Diabetes 2:

id Genetic test Affiliating Genes
1 Microvascular Complications of Diabetes 2 29

Anatomical Context for Microvascular Complications of Diabetes 2

MalaCards organs/tissues related to Microvascular Complications of Diabetes 2:

Kidney, Testes, Bone, Endothelial

Publications for Microvascular Complications of Diabetes 2

Variations for Microvascular Complications of Diabetes 2

ClinVar genetic disease variations for Microvascular Complications of Diabetes 2:

id Gene Variation Type Significance SNP ID Assembly Location
1 EPO NM_000799.3(EPO): c.-1306C> A single nucleotide variant risk factor rs1617640 GRCh38 Chromosome 7, 100719675: 100719675

Expression for Microvascular Complications of Diabetes 2

Search GEO for disease gene expression data for Microvascular Complications of Diabetes 2.

Pathways for Microvascular Complications of Diabetes 2

GO Terms for Microvascular Complications of Diabetes 2

Sources for Microvascular Complications of Diabetes 2

9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
32 HPO
33 ICD10
34 ICD10 via Orphanet
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
52 Novoseek
55 OMIM via Orphanet
59 PubMed
66 SNOMED-CT via Orphanet
68 Tocris
70 UMLS via Orphanet
Loading form....